Scott Thomas Smith, EVP & Chief Financial Officer at Ascendis Pharma A/S (ASND), bought 250 shares at $223.32 ($56K) on 2026-05-29, disclosed to the SEC on 2026-06-01.
Ascendis Pharma CFO Scott Thomas Smith purchased 250 shares for $55,830 on May 29, 2026, marking the largest purchase of his career. This rare C-suite buy comes as the stock trades near its 52-week low, potentially signaling confidence in the biotech's recovery.
ASND is down 9.19% over the past five days but remains 10.61% below its 52-week high of $250.74.
The trade marks the largest purchase in the insider's career, signaling potential confidence; additionally, J.P. Morgan highlighted the large-cap biotech sector as an inflection point on May 28, 2026.
The stock faces pressure from a 3.34% short interest and a recent $50 million exit by a fund on May 14, 2026, as noted by Motley Fool.
Something here stands out, but not much.